Hatch quizzes FDA on andro

"It appears that FDA is not taking action against [androstenedione] products because you can't decide whether it's a supplement or a drug," Sen. Orrin Hatch (R-Utah) tells FDA General Counsel Daniel Troy during an Aug. 1 Senate Judiciary committee hearing on the "Greater Access to Affordable Pharmaceuticals Act." "I'm counting on FDA moving forward on this, to protect the public health," Hatch continued, "because I think this inaction has been going on far too long." Troy promised to relay concerns to FDA Commissioner Mark McClellan, MD/PhD...